CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Jun. 29, 2025	Dec. 31, 2024
Assets
Cash and cash equivalents		$ 1,638	$ 1,043
Short-term investments		11,611	19,434
Trade accounts receivable, net of allowance for doubtful accounts: 2025—$439; 2024—$438		12,078	11,463
Inventories		11,669	10,851
Current tax assets		4,016	3,314
Other current assets		2,690	4,253
Total current assets		43,703	50,358
Equity-method investments		224	217
Long-term investments		1,896	2,010
Property, plant and equipment, net of accumulated depreciation: 2025—$17,268; 2024—$16,483		18,776	18,393
Identifiable intangible assets, net	[1]	52,702	55,411
Goodwill		68,997	68,527
Noncurrent deferred tax assets and other noncurrent tax assets		10,343	8,662
Other noncurrent assets		9,455	9,817
Total assets		206,095	213,396
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2025—$4,246; 2024—$3,747		4,295	6,946
Trade accounts payable		5,166	5,633
Dividends payable		2,445	2,437
Income taxes payable		3,675	2,910
Accrued compensation and related items		2,447	3,838
Deferred revenues		1,123	1,511
Other current liabilities		18,575	19,720
Total current liabilities		37,726	42,995
Long-term debt		57,502	57,405
Pension and postretirement benefit obligations		2,130	2,115
Noncurrent deferred tax liabilities		2,481	2,122
Other taxes payable		3,313	6,112
Other noncurrent liabilities		13,931	14,150
Total liabilities		117,083	124,899
Commitments and Contingencies
Common stock		481	480
Additional paid-in capital		94,053	93,603
Treasury stock		(115,010)	(114,763)
Retained earnings		117,609	116,725
Accumulated other comprehensive loss		(8,438)	(7,842)
Total Pfizer Inc. shareholders’ equity		88,695	88,203
Equity attributable to noncontrolling interests		317	294
Total equity		89,012	88,497
Total liabilities and equity		$ 206,095	$ 213,396

[1] The decrease is primarily due to amortization expense of $2.4 billion.